Coherent Biopharma announced that its first-in-class bispecific ligand-drug conjugate (Bi-XDC) ricorfotide vedotin (CBP-1008) has received approval from its China homeland's National Medical Products Administration (NMPA) to initiate a Phase III registrational trial for platinum-resistant ovarian cancer (PROC). The candidate targets folate receptor alpha (FRα) and TRPV6, demonstrating promising efficacy and safety in earlier studies, including a notable objective response rate (ORR) and disease control rate (DCR) in high-grade serous ovarian cancer (HGSOC) and clear cell ovarian cancer patients.

Unlike traditional antibody-drug conjugates (ADCs), ricorfotide vedotin is fully chemically synthesized, with a molecular weight about 1/50th of conventional ADCs, offering cost and manufacturing advantages. The drug has shown minimal ocular toxicity and peripheral neuropathy compared to MMAE-based ADCs. With over 300 patients enroled in clinical trials, including 227 ovarian cancer cases, ricorfotide vedotin represents a potential breakthrough for PROC patients.

According to PharmCube's NextBiopharm® database, Coherent is the only company devloping FRα×TRPV6 bispecific drugs, with two in its current pipeline. Click here to request a free trial for NextBiopharm®.